A Phase 3 Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions:   Prostate Cancer Metastatic;   Castration-resistant Prostate Cancer Interventions:   Drug: HC-1119;   Drug: Enzalutamide Sponsor:   Hinova Pharmaceuticals USA, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials